ArticleDiscover oncology2026
Ultrasound targeted microbubble delivery of JMJD2A siRNA induces ferroptosis remodels the tumor immune microenvironment and inhibits esophageal squamous cell carcinoma progression.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) remains a lethal malignancy with limited therapeutic options. JMJD2A (KDM4A) promotes tumor progression, epithelial–mesenchymal transition, and immune evasion, and it has been implicated in ferroptosis resistance. Ultrasound-targeted microbubble destruction (UTMD) can enhance local delivery of nucleic acids. We hypothesized that UTMD-mediated delivery of siRNA against JMJD2A (si-JMJD2A) would trigger ferroptosis, curb metastatic traits, remodel the tumor immune microenvironment, and improve responsiveness to anti-PD-L1 therapy.
methodssi-JMJD2A was formulated with UTMD carriers and characterized for size and surface charge. ESCC cell lines (K150 and K450) were used to assess transfection efficiency, JMJD2A knockdown, proliferation and colony formation, migration and invasion, and ferroptosis readouts, including lipid reactive oxygen species and rescue with ferroptosis inhibitors. Macrophage polarization and chemotaxis were profiled to evaluate tumor-induced immune remodeling. In vivo efficacy was tested in mouse models of ESCC, with end points including primary tumor growth, pulmonary metastasis, survival, and combination therapy with anti-PD-L1.
resultsUTMD enhanced siRNA uptake and produced robust JMJD2A silencing in ESCC cells. Functionally, si-JMJD2A delivered by UTMD suppressed proliferation, clonogenicity, migration, and invasion while inducing hallmarks of ferroptosis; these effects were mitigated by ferroptosis antagonism, supporting on-pathway activity. UTMD-si-JMJD2A reduced M2-like polarization and macrophage chemotaxis, consistent with relief of tumor-driven immune suppression. In mice, UTMD-mediated si-JMJD2A inhibited tumor growth and metastasis and improved survival. Combining UTMD-si-JMJD2A with anti-PD-L1 further enhanced antitumor efficacy compared with monotherapy.
conclusionsThis study establishes image-guided UTMD as a nonviral, localized delivery strategy for therapeutic JMJD2A silencing in ESCC. UTMD-mediated si-JMJD2A delivery induces ferroptosis, suppresses metastatic traits, and enhances the antitumor efficacy of PD-L1 blockade, supporting UTMD-enabled gene silencing as a translational approach for ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.